Lonza Group (OTCMKTS:LZAGY) Upgraded to "Hold" at Zacks Research

Key Points

• Zacks upgraded Lonza from a "strong sell" to a "hold," and Royal Bank of Canada moved the stock from "hold" to "moderate buy," leaving the MarketBeat consensus as a "Moderate Buy" (one Buy, one Hold).
• Shares opened at $64.20 and were down about 0.7%; the 50‑day and 200‑day moving averages are $65.07 and $67.06 respectively, with a 12‑month range of $58.53 to $73.85.
• Lonza is a Swiss multinational life‑sciences company focused on contract development and manufacturing (CDMO) for small molecules and biologics, serving pharmaceutical, biotech and specialty ingredients markets globally.

Lonza Group (OTCMKTS:LZAGY - Get Free Report) was upgraded by equities researchers at Zacks Research from a "strong sell" rating to a "hold" rating in a report released on Wednesday,Zacks.com reports.

Separately, Royal Bank Of Canada upgraded Lonza Group from a "hold" rating to a "moderate buy" rating in a research report on Wednesday, February 11th. One investment analyst has rated the stock with a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat.com, Lonza Group has an average rating of "Moderate Buy".

Lonza Group Stock Down 0.7%

OTCMKTS LZAGY opened at $64.20 on Wednesday. The business's 50-day moving average price is $65.07 and its 200 day moving average price is $67.06. Lonza Group has a twelve month low of $58.53 and a twelve month high of $73.85. The company has a current ratio of 2.24, a quick ratio of 1.77 and a debt-to-equity ratio of 0.42.

About Lonza Group

Lonza Group is a Swiss multinational life sciences company that provides products and services to the pharmaceutical, biotech and specialty ingredients markets. Headquartered in Switzerland, the company operates globally with manufacturing and research facilities across Europe, North America and Asia, serving customers involved in drug discovery, development and commercial production. Lonza's client base ranges from large pharmaceutical firms to emerging biotech companies and manufacturers of consumer health and specialty chemical products.

The company's core activities center on contract development and manufacturing (CDMO) for small molecules and biologics, including process development, clinical and commercial-scale manufacturing, and fill–finish services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.